Veraxa Biotech Holding (VRXA) EV/FCF: History & Chart

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T20:04:53.352Z.

Stored calculation inputs

Calculation as of: 2026-10-06T20:04:53.352Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 152,720,438
Total debt: N/A
Cash: N/A
TTM free cash flow: N/A

FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

VRXA EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

VRXA Competitors' EV/FCF Ratio

VRXA

Veraxa Biotech Holding AG

Current

Market Cap

$152.72M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CRDL

Cardiol Therapeutics Inc.

vs VRXA

Market Cap

$152.74M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MENS

Jyong Biotech Ltd. Ordinary Shares

vs VRXA

Market Cap

$153.58M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

STIM

Neuronetics, Inc.

vs VRXA

Market Cap

$153.79M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INGN

Inogen, Inc.

vs VRXA

Market Cap

$156.22M

EV/FCF Ratio

N/A

TTM Avg

55.26x

3Y Avg

38.45x

5Y Avg

50.33x

KRSA

Korsana Biosciences, Inc.

vs VRXA

Market Cap

$148.73M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VYGR

Voyager Therapeutics, Inc.

vs VRXA

Market Cap

$148.64M

EV/FCF Ratio

N/A

TTM Avg

13.24x

3Y Avg

34.58x

5Y Avg

28.14x

AVXL

Anavex Life Sciences Corp.

vs VRXA

Market Cap

$148.27M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALXO

ALX Oncology Holdings Inc.

vs VRXA

Market Cap

$146.67M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ABOS

Acumen Pharmaceuticals, Inc.

vs VRXA

Market Cap

$146.62M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Veraxa Biotech Holding AG (VRXA)	$152.72M	N/A	N/A	N/A	N/A
Cardiol Therapeutics Inc. (CRDL)vs ›	$152.74M	N/A	N/A	N/A	N/A
Jyong Biotech Ltd. Ordinary Shares (MENS)vs ›	$153.58M	N/A	N/A	N/A	N/A
Neuronetics, Inc. (STIM)vs ›	$153.79M	N/A	N/A	N/A	N/A
Inogen, Inc. (INGN)vs ›	$156.22M	N/A	55.26x	38.45x	50.33x
Korsana Biosciences, Inc. (KRSA)vs ›	$148.73M	N/A	N/A	N/A	N/A
Voyager Therapeutics, Inc. (VYGR)vs ›	$148.64M	N/A	13.24x	34.58x	28.14x
Anavex Life Sciences Corp. (AVXL)vs ›	$148.27M	N/A	N/A	N/A	N/A
ALX Oncology Holdings Inc. (ALXO)vs ›	$146.67M	N/A	N/A	N/A	N/A
Acumen Pharmaceuticals, Inc. (ABOS)vs ›	$146.62M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

VRXA EV/FCF Ratio Metrics

VRXA Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics